The treatment segment is the financial core of the Arteriovenous Malformation Market, segmented primarily into two high-cost, high-skill procedures: Endovascular Embolization and Neurosurgery. The choice between these two, or a combination thereof, depends heavily on the AVM's size, location, and the patient's overall health, driving demand for specialized instruments and expertise.

Endovascular Embolization involves threading a catheter through blood vessels to the AVM site and injecting an embolic agent (a glue-like material or particle) to block blood flow. This minimally invasive approach is often used as a pre-surgical step to reduce the size of the AVM, minimizing blood loss during open surgery, or as a primary curative treatment for smaller AVMs. The continuous innovation in flow-diverting and liquid embolic agents makes this a rapidly evolving segment of the market.

Neurosurgery remains the definitive curative treatment for AVMs that are accessible and carry a high risk of rupture. This open surgical procedure involves the complete removal of the malformation to eliminate the risk of hemorrhage. It demands highly advanced surgical equipment, including microscopy, intraoperative imaging, and patient monitoring systems, making the hospital end-user segment critical for revenue generation in this category.

The complexity of these procedures necessitates that they be performed predominantly in Hospitals & Clinics with neurosurgical expertise, reinforcing the concentration of market revenue in specialized medical centers. The rising demand for less invasive options is promoting the growth of the embolization segment, while the gold standard of complete removal keeps the neurosurgery segment vital. Analyze the treatment protocols that drive this market by consulting the full report at AVM Treatment Market.

Tags: #EndovascularEmbolization #Neurosurgery #AVMTreatment #MinimallyInvasive #Neurointerventional